Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells

Cancer Biology and Therapy

Volumn 8, Issue 10, 2009, Pages 939-950

  Fiskus, Warren ^a   Buckley, Kate ^a   Rao, Rekha ^a   Mandawat, Aditya ^a   Yang, Yonghua ^a   Joshi, Rajeshree ^a   Wang, Yongchao ^a   Balusu, Ramesh ^a   Chen, Jianguang ^a   Koul, Sanjay ^a   Joshi, Atul ^a   Upadhyay, Sunil ^a   Atadja, Peter ^b   Bhalla, Kapil N ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

DNA methyltransferase inhibitor; DNMT1; EZH2; HDAC inhibitor; hsp90

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; 5 AZA 2' DEOXYCYTIDINE; BORTEZOMIB; CD34 ANTIBODY; CHAPERONE; DNA METHYLTRANSFERASE 1; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; HEAT SHOCK PROTEIN 90; HISTONE METHYLTRANSFERASE; PANOBINOSTAT; PROTEASOME; TRANSCRIPTION FACTOR JUNB; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ARTICLE; ATTENUATION; CD34 SELECTION; CELL STRAIN K 562; CELL SURVIVAL; CELL VIABILITY; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLONOGENESIS; CONTROLLED STUDY; DNA METHYLATION; ENZYME DEGRADATION; ENZYME INHIBITION; EPIGENETICS; GENE DISRUPTION; GENE REPRESSION; GENE SILENCING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LEUKEMIA CELL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN PROTEIN INTERACTION;

AZACITIDINE; CELL SURVIVAL; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA-BINDING PROTEINS; DRUG COMBINATIONS; ENZYME INHIBITORS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; K562 CELLS; LEUKEMIA, MYELOID, ACUTE; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS;

EID: 68049144931     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.10.8213     Document Type: Article

References (65)

1. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G. Genome regulation by polycomb and trithorax proteins. Cell 2007; 128:735-45.
2. Bernstein B, Meissner A, Lander E. The mammalian epigenome. Cell 2007; 128:669-81.
3. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nature Rev Cancer 2006; 6:846-56.
4. Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 2004; 14:155-64.
5. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008.
6. Kamminga LM, Bystrykh LV, de Boer A, Houwer S, Douma J, Weersing E, et al. The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 2006; 107:2170-9.
7. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003; 22:5323-35.
8. Otte AP, Kwaks TH. Gene repression by Polycomb group protein complexes: a distinct complex for every occasion? Curr Opin Genet Dev 2003; 13:448-54.
9. van der Vlag J, Otte AP. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet 1999; 23:474-8.
10. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419:624-9.
11. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003; 100:11606-11.
12. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate and breast. J Clin Oncol 2006; 24:268-73.
13. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007; 21:1050-63.
14. Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006; 439:871-4.
15. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007; 39:232-6.
16. Ting AH, Jair K, Suzuki H, Yen R-W C, Baylin SB, Schuebel KE. Mammalian DNA methyltransferase 1: inspiration for new directions. Cell Cycle 2004; 3:1024-6.
17. Jeltsch A. On the enzymatic properties of Dnmt1: specificity, processivity, mechanism of linear diffusion and allosteric regulation of the enzyme. Epigenetics 2006; 1:63-6.
18. Svedruzic ZM. Mammalian cytosine DNA methyltransferase Dnmt1: enzymatic mechanism, novel mechanism-based inhibitors, and RNA-directed DNA methylation. Curr Med Chem 2008; 15:92-106.
19. Teodoridis JM, Hardie C, Brown R. CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett 2008; 268:177-86.
20. Robertson K. DNA methylation and chromatin-unraveling the tangled web. Oncogene 2002; 21:5361-79.
21. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-92.
22. Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T. DNA methyltransferase Dnmt1 assoicates with histone deacetylase activity. Nat Genetics 2000; 24:88-91.
23. Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-reporessor, DMAP1, to form a complex at replication foci. Nat Genetics 2000; 25:269-77.
24. Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y, et al. Expression of DNA methyltransferases DNMT-1, 3A and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001; 97:1172-9.
25. Melnick AM, Adelson K, Licht JD. The theoretical basis of transcriptional therapy of cancer: can it be put into practice? J Clin Oncol 2005; 23:3957-70.
26. Unterberger A, Andrews SD, Weaver ICG, Szyf M. DNA methyltransferase 1 knockdown activates a replication stress checkpoint. Mol Cell Biol 2006; 26:7575-86.
27. Milutinovic S, Zhuang Q, Niveleau A, Szyf M. Epigenomic stress response. Knockdown of DNA methyltransferase 1 triggers an intra-S-phase arrest of DNA replication and induction of stress response genes. J Biol Chem 2003; 278:14985-95.
28. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008; 40:741-50.
29. McGarvey KM, Greene E, Fahrner JA, Jenuwein T, Baylin SB. DNA methylation and complete transcriptional silencing of cancer genes persist after depletion of EZH2. Cancer Res 2007; 67:5097-102.
30. Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 1999; 59:3730-40.
31. Yang MY, Liu TC, Chang JG, Lin PM, Lin SF. JunB gene expression is inactivated by methylation in chronic myeloid leukemia. Blood 2003; 101:3205-11.
32. Passegué E, Wagner EF, Weissman IL. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 2004; 119:431-43.
33. Furukawa Y, Sutheesophon K, Wada T, Nishimura M, Saito Y, Ishii H, et al. Methylation silencing of the Apaf-1 gene in acute leukemia. Mol Cancer Res 2005; 3:325-34.
34. INK4b and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia. Leukemia Res 2005; 29:653-9.
35. Mariani O, Brennetot C, Coindre JM, Gruel N, Ganem C, Delattre O, et al. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell 2007; 11:361-74.
36. Issa JP. Decitabine. Curr Opin Oncol 2003; 15:446-51.
37. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, et al. Phase II study of low-dose Decitabine in patients with chronic myelogenous leukemia resistant to Imatinib Mesylate. J Clin Oncol 2005; 23:3948-56.
38. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Gen.1999; 21:103-7.
39. Belinsky SA, Klinge DM, Stidley CA, Issa JP, Herman JG, March TH, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 2003; 63:7089-93.
40. Januchowski R, Dabrowski M, Ofori H, Jagodzinski PP. Trichostatin A downregulate DNA methyltransferase 1 in Jurkat T cells. Cancer Lett 2007; 246:313-7.
41. Zhou Q, Atadja P, Davidson NE. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) expression without loss of DNA hypermethylation. Cancer Biol Ther 2007; 6:64-9.
42. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005; 280:26729-34.
43. Yang Y, Rao R, Shen J, Tang Y, Fiskus W, Nechtman J, et al. Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res 2008; 68:4833-42.
44. Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, et al. Histone deacetylase inhibitors deplete EZH2 and associated Polycomb Repressive Complex 2 proteins with attenuation of HOXA9 and MEIS1 and loss of survival of human acute leukemia cells. Mol Cancer Ther 2006; 5:3096-104.
45. Drysdale MJ, Brough PA, Massey A, Jensen MR, Schoepfer J. Targeting Hsp90 for the treatment of cancer. Curr Opin Drug Discov Devel 2006; 9:483-95.
46. Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, et al. Molecular characterization and sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-resistant, Bcr-Abl positive, human acute leukemia cells retain sensitivity to SRC kinase inhibitor PD180970 and 17-allylamino-17- demethoxygeldanomycin (17AAG). Cancer Res 2002; 62:5761-9.
47. Fiskus W, Wang Y, Joshi R, Rao R, Yang Y, Chen J, et al. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res 2008; 14:6106-15.
48. Guo F, Sigua C, Tao J, Bali P, George P, Li Y, et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004; 64:2580-9.
49. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93:9821-6.
50. Guo F, Rocha K, Bali P, Pranpat M, Fiskus W, Boyapalle S, et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res 2005; 65:10536-44.
51. Dezwaan DC, Freeman BC. HSP90: the Rosetta stone for cellular protein dynamics? Cell Cycle 2008; 7:1006-12.
52. Camphausen K, Tofilon PJ. Inhibition of Hsp90: a multitarget approach to radiosensitization. Clin Cancer Res 2007; 13:4326-30.
53. Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A, Rao R, et al. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res 2007; 13:4882-90.
54. Herranz N, Pasini D, Díaz VM, Francí C, Gutierrez A, Dave N, et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol 2008; 28:4772-81.
55. INK4a tumor suppressor gene. Genes Dev 2007; 21:49-54.
56. Schwartz YB, Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nat Rev Genet 2007; 8:9-22.
57. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008; 2:333-44.
58. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006; 66:6361-9.
59. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, et al. Phase 1/2 study of the combination of 5-aza-2′- deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108:3271-9.
60. Liu YC, Hsiao HH, Chang JG, Yang MY, Liu TC, Chang CS, et al. Usefulness of quantitative assessment of JunB gene expression as a marker for monitoring chronic myeloid leukemia patients undergoing imatinib therapy. Int J Hematol 2006; 84:425-31.
61. Chen Y, Lin MC, Yao H, Wang H, Zhang AQ, Yu J, et al. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through downregulation of stathmin. Hepatology 2007; 46:200-8.
62. Jiang X, Tan J, Li J, Kivimäe S, Yang X, Zhuang L, et al. DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 2008; 13:529-41.
63. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005; 105:1768-76.
64. Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S, et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl expressing human leukemia cells. Blood 2006; 108:645-52.
65. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007; 5:981-9.